氨甲环酸与椎板切除融合后路内固定患者失血量减少的相关性:系统评价与Meta分析
该系统评价与Meta分析检索PubMed、Web of Science和Cochrane数据库,纳入7篇文献,其中6篇共411例患者进行统计分析。最常见给药方式为术前静脉注射15 mg/kg。氨甲环酸组失血量显著减少(均数差-218.44 mL;95%CI -379.34至-57.53;p=0.018),手术时长无统计学显著缩短,两组均未报告不良事件。
要点
- 氨甲环酸组失血量较非氨甲环酸组显著减少,均数差-218.44 mL(95%CI -379.34至-57.53;p=0.018)。
- 最常见给药方式为术前静脉注射15 mg/kg,手术开始后给药方案各研究不一。
- 氨甲环酸未使手术时长出现统计学显著缩短,两组均未报告不良事件。
核心结论
- 氨甲环酸可显著减少颈椎、胸椎和腰椎椎板切除融合术的围手术期失血量,且并发症情况极少。
研究设计与样本
- 遵循PRISMA指南的系统评价与Meta分析,检索PubMed、Web of Science和Cochrane数据库。
- 共纳入7篇文献进行定性分析,其中6篇共411例患者进行统计分析。
主要发现
- 氨甲环酸组失血量较非氨甲环酸组显著减少,均数差-218.44 mL(95%CI -379.34至-57.53;p=0.018)。
- 非氨甲环酸队列较氨甲环酸队列输血增加。
- 氨甲环酸给药未使手术时长出现统计学显著缩短。
- 氨甲环酸队列与非氨甲环酸队列均未报告不良事件。
关键数值与推荐
- 氨甲环酸最常见给药途径为静脉注射,术前给予15 mg/kg。
- 手术开始后氨甲环酸的给药方案在各研究间存在差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tranexamic acid (TXA) is an antifibrinolytic agent associated with reduced blood loss and mortality in a wide range of procedures, including spine surgery, traumatic brain injury, and craniosynostosis. Despite this wide use, the safety and efficacy of TXA in spine surgery has been considered controversial due to a relative scarcity of literature and lack of statistical power in reported studies. However, if TXA can be shown to reduce blood loss in laminectomy with fusion and posterior instrumentation, more surgeons may include it in their armamentarium. The authors aimed to conduct an up-to-date systematic review and meta-analysis of the efficacy of TXA in reducing blood loss in laminectomy and fusion with posterior instrumentation. METHODS: A systematic review and meta-analysis, abiding by PRISMA guidelines, was performed by searching the databases of PubMed, Web of Science, and Cochrane. These platforms were queried for all studies reporting the use of TXA in laminectomy and fusion with posterior instrumentation. Variables retrieved included patient demographics, surgical indications, involved spinal levels, type of laminectomy performed, TXA administration dose, TXA route of administration, operative duration, blood loss, blood transfusion rate, postoperative hemoglobin level, and perioperative complications. Heterogeneity across studies was evaluated using a chi-square test, Cochran's Q test, and I2 test performed with R statistical programming software. RESULTS: A total of 7 articles were included in the qualitative study, while 6 articles featuring 411 patients underwent statistical analysis. The most common route of administration for TXA was intravenous with 15 mg/kg administered preoperatively. After the beginning of surgery, TXA administration patterns were varied among studies. Blood transfusions were increased in non-TXA cohorts compared to TXA cohorts. Patients administered TXA demonstrated a significant reduction in blood loss (mean difference -218.44 mL; 95% CI -379.34 to -57.53; p = 0.018). TXA administration was not associated with statistically significant reductions in operative durations. There were no adverse events reported in either the TXA or non-TXA patient cohorts. CONCLUSIONS: TXA can significantly reduce perioperative blood loss in cervical, thoracic, and lumbar laminectomy and fusion procedures, while demonstrating a minimal complication profile.
引用
- Brown NJ, Choi EH, Gendreau JL, et al. Association of tranexamic acid with decreased blood loss in patients undergoing laminectomy and fusion with posterior instrumentation: a systematic review and meta-analysis. J Neurosurg Spine. 2021. PMID: 34740174. doi:10.3171/2021.7.SPINE202217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。